U.S. markets open in 6 hours 32 minutes

Landos Biopharma, Inc. (LABP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
15.24+0.87 (+6.05%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close14.37
Open14.26
Bid0.00 x 1300
Ask0.00 x 900
Day's Range13.60 - 16.24
52 Week Range10.77 - 16.99
Volume393,584
Avg. Volume631,394
Market Cap596.847M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Barrons.com

      Bausch Health and Landos Biopharma See Activist Action

      Icahn Capital reached a pact to appoint Bausch Health directors. Perceptive Advisors disclosed a large stake in Landos Biopharma.

    • Landos Biopharma to Participate in the SVB Leerink 10th Annual Global Healthcare Conference
      GlobeNewswire

      Landos Biopharma to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

      BLACKSBURG, Va., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (Nasdaq: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced that Dr. Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer, will participate in a fireside chat at the upcoming virtual SVB Leerink 10th Annual Global Healthcare Conference on Wednesday, February 24, 2021 at 12:00 PM EST. A live webcast of the fireside chat will be accessible through the Investors/Media section of the Company’s website at www.landosbiopharma.com. Following the event, the webcast will be archived on the Landos website. About Landos Biopharma Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases that are the first to target new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Landos Biopharma’s core expertise is in the development of therapeutic candidates targeting novel pathways at the interface of immunity and metabolism. Lead asset BT-11 is a novel, oral, gut-restricted small molecule therapeutic candidate for the treatment of ulcerative colitis and Crohn’s disease that targets the LANCL2 pathway. NX-13 is a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. Additional candidates are in development for the treatment of lupus nephritis, rheumatoid arthritis, multiple sclerosis, and diabetes. Contacts: Thomas Hoffmann (investors) Solebury Trout646-378-2931thoffmann@troutgroup.com Hannah Gendel (media)Solebury Trout646-378-2943hgendel@troutgroup.com

    • Barrons.com

      The Wave of Biotech IPOs Continues. Here Are 7 Stocks That Hit the Market

      A flock of biotech companies are opening for trading Friday. Most of the deals grew in size, with price increases as well. Vor Biopharma stock rocketed at its open.